Impact21

Molecule2Market, located in Kew, Victoria, is a privately owned Australian Clinical Research Organization (CRO) dedicated to advancing medical innovations through expert clinical research services. With over 60 years of combined experience among its directors and a team of specialists, the organization supports pharmaceutical, biotechnology, and medtech industries in navigating the complexities of clinical trials. Their services encompass various phases of clinical research, including project feasibility, site selection, study startup, and patient recruitment, all while ensuring adherence to high standards and regulatory requirements. Utilizing a broad network of partners, Molecule2Market aims to facilitate efficient clinical development outcomes and enhance the global expansion of innovative therapies. Generated from the website